Breaks Categories: News

FridayJun 28, 2024 12:38 pm

BioMedNewsBreaks — VolitionRx Limited (NYSE American: VNRX) Highlights Latest Achievements in Mid-Year Review

  VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, has released a mid-year review that highlights significant milestones, such as the expansion of the Nu.Q(R) Vet Cancer Test, which is now available for purchase in 15 countries. Additionally, Volition is engaged in active commercial discussions with significant players in the fields of liquid biopsy and in vitro diagnostics (“IVD”), for sepsis, and oncology. Cameron Reynolds, President and Group Chief Executive Officer of Volition, emphasized the successful support provided to veterinary licensing and distribution partners…

Continue Reading

ThursdayJun 27, 2024 3:44 pm

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval

  FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcement, the human ethics review committee (“HREC”) in Australia approved the trial, which is titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A first-in-class, nonimmunomodulatory, neuroprotective compound, Lucid-21-302 offers a unique mechanism of action for the treatment of multiple sclerosis (“MS”). “After much…

Continue Reading

ThursdayJun 27, 2024 9:35 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is announcing the filing of a provisional patent. This patent covers the manufacturing process of new solid forms of buntanetap (formerly known as Posiphen or ANVS401), which targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins. According to the announcement, the patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1) as well as the entire synthesis process, from basic starting materials to finished (>99.9% pure) GMP product, suitable for manufacturing scale at ton…

Continue Reading

WednesdayJun 26, 2024 2:40 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed a patent with the U.S. Patent and Trademark Office. The patent covers novel solid forms of buntanetap, selecting the best crystal and building upon the provisional patent the company filed in June 2023. Formerly known as posiphen or ANVS401, buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins connected with disease, including amyloid beta, tau, alpha-synuclein and TDP43. Through this process, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s and other…

Continue Reading

WednesdayJun 26, 2024 2:13 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Announces New COO, Appoints Seasoned Veteran to Enhance Operations and Drive Initiatives

  HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has announced a new chief operating officer. According to the announcement, the company has promoted Bill Crupi to the position, effective immediately. Crupi joined the company last year and has been instrumental in optimizing operational efficiencies and supporting the company's growth trajectory. Crupi has more than 20 years’ experience working in the healthcare industry and has served in several operational management leadership roles. In his new role, Crupi will manage the daily operations of HealthLynked, with a specific focus on enhancing operational efficiencies, driving strategic initiatives and ensuring the…

Continue Reading

TuesdayJun 25, 2024 1:47 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is hosting an investor webcast. During the webcast, Annovis Bio officials will discuss recent developments and future plans for its lead drug candidate, Buntanetap, which targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. Management will also talk about strategic plans for upcoming clinical trials and provide an overview of the company’s progress and future direction. The webcast is scheduled for 4:30 p.m. ET on July 2, 2024. To view the…

Continue Reading

MondayJun 24, 2024 2:03 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will be featured at this week’s H.C. Wainwright’s Fifth Annual Neuro Perspectives Virtual Conference. According to the announcement, Clene management will be presenting a fireside chat and will host one-on-one investor meetings during the June 27, 2024, online event. The presentation will be available upon demand the day of the conference, with a webcast of the presentation also found on the Clene website. To…

Continue Reading

FridayJun 21, 2024 3:42 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents New Preliminary Data Demonstrating Potential of CNM-Au8(R) as Treatment for Rett Syndrome

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene today announced that Karen Ho, Ph.D., the company’s vice president of translational medicine, presented new, preliminary data demonstrating the potential of CNM-Au8(R) as a treatment for Rett Syndrome, a severe, rare pediatric neurologic disorder. Dr. Ho unveiled the data in oral and poster presentations on June 19 at the International Rett Syndrome Foundation 2024 Annual Meeting…

Continue Reading

ThursdayJun 20, 2024 3:57 pm

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) TRACER 1000(TM) Receives ‘Approved’ Status on Air Cargo Security Technology List

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the U.S. Transportation Security Administration (“TSA”) has approved the TRACER 1000(TM) for the Air Cargo Security Technology List (“ACSTL”) following thorough assessment by the TSA QG2 Technical Review Panel (“TRP”). Following the approval, regulated parties in the U.S., such as the air cargo market, which are required to use the ACSTL, can now purchase the TRACER 1000. This approval, the announcement noted, advances the TRACER 1000 to Stage II testing. Once the field testing is successfully completed, the TRACER 1000 will move to the “Qualified” section…

Continue Reading

ThursdayJun 20, 2024 11:11 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, today provided an update on its AVERSA(TM) Fentanyl product development program. This comes as the company plans to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to a New Drug Application (“NDA”) filing. According to the update, Nutriband is currently working with its partner Kindeva Drug Delivery to develop the commercial scale manufacturing process for the final product, which will incorporate Nutriband’s AVERSA(TM) abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. The update noted…

Continue Reading